Clinical Effectiveness of First-Line Anti-TNF Therapies and Second-Line Anti-TNF Therapy Post-Vedolizumab Discontinuation in Patients with Ulcerative Colitis or Crohn's Disease
Brian Bressler 1
Andres Yarur 2
Uri Kopylov 3
Marielle Bassel 4
Neil Brett 4
Trevor Lissoos 5
claudia lopez 5
Athanasios Natsios 6
Sumit Saha
Christina Kifnidi
Dirk Demuth
Haridarshan Patel
Gerassimos J. Mantzaris
1 University of British Columbia,Vancouver,Canada
2 Medical College of Wisconsin,Milwaukee,United States
3 Chaim Sheba Medical Center,Ramat Gan,Israel
4 Evidera,Montreal,Canada
5 Takeda Pharmaceuticals USA Inc,Deerfield,United States
6 Takeda Hellas S.A.,Athen
Session
IBD II (Posters)
Conference
UEG Week 2019
Citation
United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019
Login to access library content
Do you need help setting up your myUEG account?
Contact us at office@ueg.eu